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(comparison cohort) who were the same age, race, and gender were identified and 
matched. A random index date was chosen to minimize selection bias. Patients in 
both cohorts were required to be at least age 18 years, with continuous medical and 
pharmacy benefits 1-year pre- and 1-year post-index date. One-to-one propensity 
score matching (PSM) was used to compare health care costs and utilizations during 
the follow-up period, between the diseased and comparison cohorts, and adjusted 
for baseline demographic and clinical characteristics. Results: After risk adjust-
ment by PSM, a total of 19,079 patients in each cohort were matched. Significantly 
more breast cancer patients had inpatient admissions (23.77% vs. 12.56%, p< 0.0001) 
and long-term care (7.77% vs. 6.60%, p< 0.0001), other service (99.88% vs. 87.86%, 
p< 0.0001) and pharmacy visits (77.80% vs. 68.85%, p< 0.0001), compared to those 
without breast cancer. Breast cancer patients also incurred significantly higher 
inpatient ($2,141 vs. $1,537, p< 0.0001), long-term care ($7,471 vs. $5,335, p< 0.0001), 
other service visit ($23,592 vs. $14,780, p< 0.0001) and pharmacy costs ($3,379 vs. 
$2,787, p< 0.0001) compared to those in the comparison cohort. ConClusions: 
Breast cancer patients in the Medicaid program incurred substantially higher health 
care resource utilization and costs compared to those without the disease.
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objeCtives: Paclitaxel and docetaxel are used for the treatment of MBC in China. 
However, one important drawback, particularly with docetaxel, is the potential for 
dose-limiting toxicity. To improve the side effect profile and efficacy of paclitaxel, 
an albumin-bound formulation (nab-paclitaxel) is currently available in China 
(Abraxane®). Clinical trials have demonstrated that nab-paclitaxel is safer and more 
effective than both docetaxel and paclitaxel. To provide economic data for China, 
a cost utility analysis comparing nab-paclitaxel to docetaxel, both as alternatives 
to paclitaxel was conducted. Methods: Clinical data was obtained from a meta 
analysis of randomized trials comparing either nab-paclitaxel (260 mg/m2 q3wk) 
or branded docetaxel (100 mg/m2 q3wk) to solvent-based branded paclitaxel (175 
mg/m2 q3wk). Health care resource use for the delivery of chemotherapy and the 
management of grade 3/4 toxicity was collected from a time and motion study 
in three Chinese cancer centers and from a survey of clinicians. Using the Time 
Trade-off technique, treatment preferences and utility estimates were obtained 
from interviewing 28 cancer patients from two centres in China. All costs were 
reported in 2014 $U. S. Results: Nab-paclitaxel had the most favourable safety 
profile characterized with the lowest incidence of grade 3/4 neutropenia, febrile 
neutropenia, anemia and stomatitis. This translated into lower costs for managing 
the grade 3/4 side effects of nab-paclitaxel relative to both docetaxel and paclitaxel 
($21 vs. $166 vs. $81). In the preference assessment, 22 of 28 (78.6%) patients selected 
nab-paclitaxel as their preferred agent. As an alternative to paclitaxel, the cost per 
quality adjusted life year (QALY) gained was more favourable with nab-paclitaxel 
than docetaxel ($57,900 vs. $130,600 respectively). ConClusions: Nab-paclitaxel is 
an economically attractive alternative to paclitaxel and docetaxel in MBC, providing 
a substantially lower cost per QALY. Additionally in the patient preference survey, 
78.6% of patients selected nab-paclitaxel as their preferred agent.
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objeCtives: Targeted therapy with ALK inhibitor crizotinib offers significant 
improvement in clinical outcome for treatment of EML4–ALK fusion positive non-
small cell lung cancer (NSCLC) patients. We estimated the cost-effectiveness of 
companion EML4-ALK genetic testing in combination with crizotinib treatment in 
the second-line setting for advanced NSCLC in Ontario. Methods: We performed 
a cost-effectiveness analysis using a Markov model from a Ministry of Health per-
spective and a lifetime horizon. Transition probabilities and mortality rates were 
calculated based on the data of a recent second-line randomized trial of crizotinib 
versus chemotherapy (Shaw et al. New Engl J Med 2013). Costs were obtained from 
OCCI database, public labs and Princess Margaret Hospital. All parameters were 
varied separately in one-way and selected two-way sensitivity analyses. Various 
scenarios to assess the impact of model assumptions about testing and treatment 
were conducted. Results:  The use of pemetrexed and docetaxel in ALK-rearranged 
NSCLC, based on our preliminary model, could yield as much as 0.539 QALY and 
0.429 QALY respectively, assuming no crossover from chemotherapy to crizotinib. 
Average costs per patient based on the preliminary model are estimated at CAD 
$19,388 for pemetrexed and $$33,226for docetaxel, with incremental cost-effective-
ness ratios of $333,595/QALY and $125,812/QALY gained respectively. The results of 
the one-way sensitivity analysis indicated that the primary drivers of the ICER were 
the utilities and cost of crizotinib treatment. The model was least sensitive to IHC 
and FISH genetic test costs, re-biopsy cost, probability of progression while on pem-
etrexed treatment and probability of re-biopsy. ConClusions: EML4–ALK genetic 
testing in combination with crizotinib treatment for all NSCLC patients eligible for 
chemotherapy is not economically attractive in the current setting. Lower drug costs 
would be required to make this strategy economically feasible.
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incremental quality-adjusted life years (QALYs) while ESAs were administered 
and during a Hb “normalisation period” following cancer treatment. Incremental 
long-term QALYs were accrued solely through extrapolated overall survival. Short-
term mortality and HRQoL associated with adverse events and RBCTs were not 
modelled. Costs included: ESA acquisition (list prices, British National Formulary) 
and administration, RBCT, additional blood tests with ESA therapy, and adverse 
event costs. Results: All ESAs except epoetin beta and darbepoetin alfa were 
cost-effective versus using RBCT only at an upper cost-effectiveness threshold of 
£30,000/QALY. Incremental cost-effectiveness ratios (ICERs) ranged from £19,400/
QALY (biosimilar epoetin alfa) to £35,000/QALY (epoetin beta). Probabilistic sensi-
tivity analysis showed that biosimilar epoetin alfa was cost-effective at the lower 
cost-effectiveness threshold of £20,000/QALY in 50.9% of simulations. In 19.5% of 
simulations it was clinically effective but not cost-effective and in 31.4% of simula-
tions it was dominated by RBCT only. Additional sensitivity analyses demonstrated 
that overall survival was one of the most influential and uncertain parameters. 
When the survival advantage of ESAs (not statistically significant) was removed, the 
ICERs for all ESAs were over £100,000/QALY. ConClusions:  There is substantial 
uncertainty regarding the impact of ESA therapy on overall survival, which leads to 
significant uncertainty about the cost-effectiveness of ESAs in CIA.
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objeCtives: To demonstrate the impact of QALY weightings based on the burden-of-
illness (BoI) of pancreatic cancer on the incremental cost-effectiveness ratio (ICER) of 
nab-paclitaxel plus gemcitabine (NPG) versus gemcitabine (G). Methods: A markov 
model using data from the MPACT trial plus resource use data and costs from NHS 
Scotland have been submitted to the Scottish Medicines Consortium. The base case 
ICER was £52,885/QALY based on a cost of £8,232 and a QALY gain of 0.156 (SMC DAD). 
QALY weightings up to a maximum of 2.5 distributed across six modifier factors, 
including BoI, have been proposed (NICE consultation on Value Based Assessment), 
with BoI measured according to proportional QALY shortfall associated with the con-
dition. The estimated 98% loss of healthy life (proportional QALY shortfall) in pan-
creatic cancer (Hutchings 2014) represents an almost complete loss of life, and thus 
a very high BoI. A BoI weighting of 2.5 (maximum weighting allocated entirely to BoI, 
or BoI FULL) and an alternative BoI weighting of 1.417 (maximum weighting shared 
equally between six modifiers, so 1/6thof 2.5, or BoI PARTIAL) were therefore applied to 
the QALY gain of NPG versus G. Results:  The BoI FULL weighting gives an adjusted 
QALY gain for NPG versus G of 0.39 and a corresponding ICER of £21,108/QALY. The 
BoI PARTIAL weighting gives an adjusted QALY gain for NPG versus G of 0.221 and 
a corresponding ICER of £37,249/QALY. ConClusions: Various ways of accounting 
for disease severity can be considered and made workable by HTAs, including QALY 
weightings according to proportional QALY shortfall. The adjusted QALY gain and 
corresponding ICERs of NPG versus G in pancreatic cancer show that the value of 
medicines for life-threatening ‘end-of-life’ conditions with a high relative shortfall 
can be reflected by an appropriate system of QALY weightings.
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objeCtives: The objective of the current analysis was to assess the cost-effective-
ness of lapatinib plus capecitabine versus capecitabine alone in human epidermal 
growth factor receptor-2-positive metastatic breast cancer patients from the third 
party payer perspective over a time horizon of ten years. Methods: A half cycle 
corrected Markov chain model comprising 3 health states (stable, progression and 
death) was developed to estimate the projected clinical and economic implications 
of Lapatinib. Transition probabilities were estimated based on the results from the 
EGF100151 clinical trial of Lapatinib. Health state utilities and major adverse events 
were obtained from published sources. Direct medical costs were obtained from the 
third party payer list. Costs (in 2013 EGP) and effects were discounted at 3.5% annu-
ally. One way sensitivity analyses were conducted. Results:  The economic evalu-
ation of lapatinib plus capecitabine as combination therapy resulted in additional 
cost of 1,597,796 EGP, with an incremental positive effect of 5.7 quality adjusted life 
years (QALY) or an incremental cost-effectiveness ratio (ICER) of 277,169 EGP/QALY 
gained. The overall survival of the two arms was found to have the greatest impact 
on the results. ConClusions: Compared with our willingness-to-pay threshold 
stated by world health organization for middle and lower income countries, the 
addition of lapatinib to capecitabine is not clearly cost-effective; and most likely to 
result in an ICER higher than the threshold limit.
PCN160
health Care UtilizatioN aND Costs of breast CaNCer iN the MeDiCaiD 
PrograM
Li L.1, Shrestha S.1, Baser O.2, Wang L.1
1STATinMED Research, Plano, TX, USA, 2STATinMED Research and The University of Michigan, 
Ann Arbor, MI, USA
objeCtives: To evaluate health care resource utilization and costs among patients 
diagnosed with breast cancer in the Medicaid program. Methods: Patients diag-
nosed with breast cancer (International Classification of Disease, 9thRevision, 
Clinical Modification [ICD-9-CM] diagnosis code 174, 233.0, 238.3, 239.3) were identi-
fied using Medicaid data from January 1, 2008 through December 31, 2010. The initial 
diagnosis date was designated as the index date. Patients without breast cancer 
